Abstract: A glaucoma treatment system includes: a cannula body configured to be positioned in an area of Schlemm's canal; an illumination guide extending along the cannula body; at least one drug source coupled to the cannula body; a cross-linking agent source coupled to the cannula body; and an illumination source coupled to the illumination guide. The at least one drug source includes a drug that promotes outflow of aqueous humor through the trabecular meshwork and into Schlemm's canal. The cannula body delivers the drug from the at least one drug source to the area of Schlemm's canal, and in response to changes in the outflow of aqueous humor, delivers the cross-linking agent to the area of Schlemm's canal. The illumination guide delivers photo-activating light from the illumination source to the area of Schlemm's canal. The photo-activating light activates the cross-linking agent, thereby stabilizing changes in the area of Schlemm's canal.

Abstract: System and methods for a corrective eye procedure include at least one application device configured to be positioned at a selected area of an eye (e.g., equatorial sclera, posterior sclera, cornea, etc.). The at least one device includes at least one channel and at least one illumination guide. A cross-linking agent source is coupled to the at least one channel. An illumination source is coupled to the at least one illumination guide. The at least one device delivers the cross-linking agent to the selected area of the eye. The at least one device delivers photo-activating light from the illumination source to the selected area of the eye after the cross-linking agent has been delivered. The photo-activating light includes one or more doses necessary for activating the cross-linking agent and for activating TGF-? isoforms to improve health of extracellular matrices in the selected area of the eye.

Abstract: An electronic device includes a non-volatile memory having a plurality of memory cells, a memory controller, and an evaluator. The memory controller is configured to provide control signals to the non-volatile memory causing the non-volatile memory, or a selected memory section of the non-volatile memory, to be in one of a read state and a weak erase state, wherein the weak erase state causes the plurality of memory cells to maintain different states depending on different physical properties of the plurality of memory cells. The evaluator is configured to read out the plurality of memory cells and to provide a readout pattern during the read state, wherein the readout pattern that is provided after a preceding weak erase state corresponds to a physically unclonable function (PUF) response of the electronic device uniquely identifying the electronic device.

Abstract: An electrical energy applicator in one embodiment extends from a proximal end to a distal end. The energy conducting applicator includes, at the proximal end, a connection to one or more electrical energy sources. The energy conducting applicator directs electrical energy from the one or more electrical energy sources to the distal end. The energy conducting applicator includes an outer conductor and an inner conductor extending to the distal end. The outer conductor and the inner conductor are separated by a gap. The outer conductor includes a plurality of moveable outer segments and the inner conductor includes a plurality of moveable inner segments. The plurality of outer segments and the plurality of inner segments form a total contact surface at the distal end. The total contact surface is positionable at a surface of an eye. The electrical energy is applied to the eye according to the total contact surface.

Abstract: According to aspects of the present disclosure, a kit for transepithelial delivery of a cross-linking agent to a cornea includes a first vessel containing an initial formulation that includes a cross-linking agent and a first active ingredient configured to open corneal epithelial tight junctions when applied to a cornea and one or more second vessels each containing a respective secondary formulation that includes the cross-linking agent for application to the cornea after the initial formulation is applied to the cornea.

Abstract: An internal anatomic target that is infected by pathogenic microorganisms is treated using an applicator configured for delivering a therapeutic solution thereto and an UV light-emitting device transmits UV light thereon.

Abstract: Systems and methods for treating an eye select locations for making incisions in areas of the cornea according to astigmatic keratotomy or radial keratotomy, make incisions in the selected areas of the cornea, apply a cross-linking agent to the selected areas of the cornea, and deliver photoactivating light from a light source to the selected areas of the cornea to initiate cross-linking activity in the selected areas of the cornea.

Abstract: A system for applying therapy to an eye selectively applies coolant to the corneal surface to minimize heat-related damage to the corneal surface during thermokeratoplasty. Embodiments may include an energy source, a conducting element, a coolant supply, and a coolant delivery system. The conducting element is operably connected to the energy source and extends from a proximal end to a distal end. The conducting element directs energy from the energy source to the distal end, which is positionable at the eye. The coolant delivery system is in communication with the coolant supply and is operable to deliver a micro-controlled pulse of coolant to the distal end.

Abstract: Embodiments apply a cross-linking agent to a region of corneal tissue. The cross-linking agent improves the ability of the corneal tissue to resist undesired structural changes. For example, the cross-linking agent may be Riboflavin or Rose Bengal, and the initiating element may be photoactivating light, such as ultraviolet (UV) light. In these embodiments, the photoactivating light initiates cross-linking activity by irradiating the applied cross-linking agent to release reactive oxygen radicals in the corneal tissue. The cross-linking agent acts as a sensitizer to convert O2 into singlet oxygen which causes cross-linking within the corneal tissue. The rate of cross-linking in the cornea is related to the concentration of O2 present when the cross-linking agent is irradiated with photoactivating light. Accordingly, the embodiments control the concentration of O2 during irradiation to increase or decrease the rate of cross-linking and achieve a desired amount of cross-linking.

Abstract: Heat is generated in corneal fibrils in a cornea of an eye according to a selected pattern. The heat causes the corneal fibrils corresponding to the selected pattern to transition from a first structure to a second structure. The second structure provides a desired reshaping of the cornea. A cross-linking agent is then activated in the region of corneal fibrils according to the selected pattern. The cross-linking agent prevents the corneal fibrils from changing from the second structure. Thus, embodiments stabilize corneal tissue and improve its biomechanical strength after desired structural changes have been achieved in the corneal tissue. Accordingly, the embodiments help to preserve the desired reshaping of the cornea.

Abstract: Techniques are provided for use with an implantable medical device for delivering left atrial (LA) pacing to address Diastolic Heart Failure, also referred to as Heart Failure with Preserved Ejection Fraction. In one example, pulse delivery times are selected for delivery of LA pacing pulses sufficient so that activation of the LA occurs when LA pressure (LAP) is lower than would occur in the absence of LA pacing. The pulse delivery times and also set so that subsequent activation of the right ventricle (RV) occurs when LAP is lower than would occur in the absence of LA pacing. LA pacing then is delivered by the implanted device at the selected pulse delivery times to mitigate Diastolic Heart Failure or to address other conditions.

Abstract: Embodiments apply a cross-linking agent to a region of corneal tissue. The cross-linking agent improves the ability of the corneal tissue to resist undesired structural changes. For example, the cross-linking agent may be Riboflavin or Rose Bengal, and the initiating element may be photoactivating light, such as ultraviolet (UV) light. In these embodiments, the photoactivating light initiates cross-linking activity by irradiating the applied cross-linking agent to release reactive oxygen radicals in the corneal tissue. The cross-linking agent acts as a sensitizer to convert O2 into singlet oxygen which causes cross-linking within the corneal tissue. The rate of cross-linking in the cornea is related to the concentration of O2 present when the cross-linking agent is irradiated with photoactivating light. Accordingly, the embodiments control the concentration of O2 during irradiation to increase or decrease the rate of cross-linking and achieve a desired amount of cross-linking.

Abstract: A system for multimodal biometric identification has a first imaging system that detects one or more subjects in a first field of view, including a targeted subject having a first biometric characteristic and a second biometric characteristic; a second imaging system that captures a first image of the first biometric characteristic according to first photons, where the first biometric characteristic is positioned in a second field of view smaller than the first field of view, and the first image includes first data for biometric identification; a third imaging system that captures a second image of the second biometric characteristic according to second photons, where the second biometric characteristic is positioned in a third field of view which is smaller than the first and second fields of view, and the second image includes second data for biometric identification. At least one active illumination source emits the second photons.

Abstract: Various endoscopes are integrated with an applicator configured for delivering a therapeutic solution to an internal anatomic target that may be infected by pathogenic microorganisms and a UV light-emitting device transmitting UV light thereto.

Abstract: Heat is generated in corneal fibrils in a cornea of an eye according to a selected pattern. The heat causes the corneal fibrils corresponding to the selected pattern to transition from a first structure to a second structure. The second structure provides a desired reshaping of the cornea. A cross-linking agent is then activated in the region of corneal fibrils according to the selected pattern. The cross-linking agent prevents the corneal fibrils from changing from the second structure. Thus, embodiments stabilize corneal tissue and improve its biomechanical strength after desired structural changes have been achieved in the corneal tissue. Accordingly, the embodiments help to preserve the desired reshaping of the cornea.

Abstract: A method for controlling activation of a cross-linking agent applied to an eye includes applying the cross-linking agent to a selected region of a cornea of the eye and initiating cross-linking activity in the selected region by activating the cross-linking agent with pulsed light illumination. The pulsed light illumination has a selectable wavelength, irradiance, dose, and on/off duty cycle. The wavelength, the irradiance, the dose, and the on/off duty cycle are adjusted in response to a determination of photochemical kinetic pathways for cross-linking activity and to control photochemical efficiency, depth of cross-linking, and density of cross-linking.

Abstract: A method for forming a heterostructure includes forming a first perovskite crystal structure complex oxide material layer over a substrate to a first thickness. A second perovskite crystal structure oxygen deficient complex oxide oxygen getter material layer is formed upon the first perovskite crystal structure complex oxide material layer. When the second perovskite crystal structure oxygen deficient complex oxide oxygen getter material layer reaches a critical thickness that may approximate one-half to one times the first thickness, the first perovskite crystal structure complex oxide material layer spontaneously transforms into a first brownmillerite crystal structure complex oxide material layer, with an attendant transfer of substantially one-half oxygen atom per perovskite unit cell to the second perovskite crystal structure oxygen deficient complex oxide oxygen getter material layer, thus forming a second perovskite crystal structure oxygen enriched complex oxide oxygen getter material layer.

Abstract: Embodiments apply light energy in medical treatments. To enhance or control the effect of the light energy, embodiments apply the light energy after tissue has been treated, e.g., with a photosensitizing agent. For example, embodiments may treat target tissue with riboflavin before exposure to ultraviolet light. For example, a system for cataract surgery includes a removal system configured to remove a first lens from an eye, wherein a capsular bag remains in the eye after removal of the first lens. The system includes an application system configured to treat lenticular epithelial cells in the capsular bag with the photosensitizing agent. The system includes a delivery system with a light source and an optical device. The optical device delivers light to the treated lenticular epithelial cells. Energy from the light destroys the lenticular epithelial cells in the capsular bag to reduce the growth of epithelial cells that cause posterior capsule opacification.

Abstract: A system for aligning an eye therapy instrument over a selected area or feature of an eye provides an attachment element that is removably attached to a surface of an eye. A receiving element is coupled to the attachment element and movable relative to the attachment element. The receiving element includes a coupling element configured to operably couple an eye therapy instrument to the receiving element and adjustably move the eye therapy instrument into a selected position with respect to the attachment element. The system makes adjustments to ensure accurate delivery of treatment from the eye therapy device to areas of the eye. In one embodiment, the receiving element allows lateral adjustments to be made along one or more axes. Additionally or alternatively, the receiving element allows angular or rotational adjustments to be made about one or more axes.

Abstract: A system includes a conducting element that conducts energy from an energy source to apply therapy to an eye. The system includes a covering configured to be removably attached to the conducting element. The covering has an interface surface that is positionable at an eye. At least a portion of the interface surface includes one or more dielectric materials. Energy is deliverable to the eye through the interface surface. In one aspect, the covering provides an electrical insulator to minimize the concentration of electrical current in the area of contact with the eye. In another aspect, the covering allows the eye to be cooled during the application of energy without directly applying coolant to the eye. In another aspect, the covering includes a dielectric layer that may provide varying impedances that allow different patterns for energy delivery. In another aspect, the sheath promotes hygienic use of the conducting element.